


Ask a doctor about a prescription for MOXIFLOXACIN KERN PHARMA 400 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Moxifloxacino Kern Pharma 400 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
Moxifloxacino Kern Pharma contains moxifloxacino as the active substance, which belongs to the group of antibiotics known as fluoroquinolones. Moxifloxacino Kern Pharma acts by eliminating bacteria that cause infections.
Antibiotics are used to treat bacterial infections and are not effective against viral infections such as the flu or common cold.
It is essential that you follow the instructions regarding dosage, administration interval, and treatment duration indicated by your doctor.
Do not store or reuse this medication. If you have any leftover antibiotic after completing treatment, return it to the pharmacy for proper disposal. Do not throw medications down the drain or in the trash.
Moxifloxacino Kern Pharma is indicated in patients 18 years and older for the treatment of bacterial infections when moxifloxacino is active against certain bacteria. Moxifloxacino Kern Pharma should only be used to treat such infections when usual antibiotics cannot be used or have not worked.
Treatable infections include: sinus infection, sudden worsening of long-term airway inflammation or lung infection (pneumonia) acquired outside the hospital (except severe cases).
Mild or moderate infections of the upper female genital tract (pelvic inflammatory disease), including fallopian tube infection and uterine mucous membrane infection. For this type of infection, Moxifloxacino Kern Pharma tablets are not sufficient as sole treatment; therefore, in addition to Moxifloxacino Kern Pharma, your doctor will prescribe another antibiotic for the treatment of mild or moderate upper female genital tract infections.
If the following diseases have shown improvement during initial treatment with Moxifloxacino Kern Pharma solution for infusion, your doctor may prescribe Moxifloxacino Kern Pharma tablets to complete the treatment: lung infection (pneumonia) acquired outside the hospital, skin and soft tissue infections.
Moxifloxacino Kern Pharma tablets should not be used to initiate treatment for any type of skin and soft tissue infection or severe lung infections.
Consult your doctor if you are not sure if you belong to one of the patient groups described below.
Do not take Moxifloxacino Kern Pharma
Warnings and precautions
Before starting to take this medicine
You should not take antibacterial medicines that contain fluoroquinolones or quinolones, including moxifloxacino, if you have experienced a severe adverse reaction previously when taking a quinolone or a fluoroquinolone. If this is the case, you should inform your doctor as soon as possible.
Consult your doctor or pharmacist before starting to take Moxifloxacino Kern Pharma.
Consult an ophthalmologist immediately if you experience any vision changes or have any eye problems.
During treatment withthismedicine:
If you experience any of these side effects after taking moxifloxacino Kern Pharma, contact your doctor immediately before continuing treatment. You and your doctor will decide whether to continue or not, also considering the use of an antibiotic of another class.
Severe skin reactions
Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS or drug hypersensitivity syndrome), have been reported with the use of moxifloxacino.
If you develop a severe rash or any of these skin symptoms, stop taking moxifloxacino and contact your doctor or seek medical attention immediately.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years old because the efficacy and safety have not been established for this age group (see section Do not take Moxofloxacino Kern Pharma).
Other medicines and Moxifloxacino Kern Pharma
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicine.
With Moxifloxacino Kern Pharma, you should consider the following:
Using Moxifloxacino Kern Pharma with food and drinks
The effect of this medicine is not altered by food, including dairy products.
Pregnancy, breastfeeding, and fertility
Do not use this medicine during pregnancy or breastfeeding.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Animal studies do not indicate that fertility may be altered by taking this medicine.
Driving and using machines
Moxifloxacino may cause dizziness or vertigo or a brief fainting spell; you may experience a sudden transient loss of vision. If you experience these symptoms, do not drive vehicles or operate machinery.
Moxifloxacino Kern Pharma contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet, i.e., it is essentially "sodium-free".
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose in adults is one 400 mg film-coated tablet, once a day.
Moxifloxacino tablets are for oral use. Take the tablet whole without chewing (to mask the bitter taste) and with plenty of liquid. This medication can be taken with or without food. It is recommended that you take the tablet at approximately the same time every day.
No dose adjustment is necessary in elderly patients, in patients with low body weight, or in patients with kidney problems.
The duration of treatment depends on the type of infection. Unless your doctor has indicated otherwise, the duration of treatment with Moxifloxacino Kern Pharma is as follows:
When moxifloxacino is used to complete a treatment started with moxifloxacino solution for infusion, the recommended durations are:
Most patients with pneumonia switched from intravenous to oral treatment after 4 days.
Most patients with skin and soft tissue infections switched from intravenous to oral treatment after 6 days.
It is important to complete the full treatment, even if you start to feel better after a few days.
Do not exceed the recommended dose and duration of treatment.
If you take more Moxifloxacino Kern Pharma than you should
If you take more than one of the recommended tablets per day, consult your doctor immediately and, if possible, take the remaining medication, packaging, or this leaflet and show it to your doctor or pharmacist what you have taken.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Moxifloxacino Kern Pharma
In case of forgetting a dose, you should take the tablet as soon as you remember it on the same day. If you do not take your tablet one day, take the normal dose (one tablet) the next day. Do not take two tablets to make up for the forgotten dose.
If you are not sure what to do, consult your doctor or pharmacist.
If you interrupt treatment with Moxifloxacino Kern Pharma
If you interrupt the treatment too early, your infection may not be completely cured, the infection may return, or your condition may worsen, and you may also develop bacterial resistance to the antibiotic. Consult your doctor if you intend to stop taking the tablets before completing the full treatment.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not all people experience them. During treatment with moxifloxacino, the following side effects have been observed. The assessment of side effects is based on the following frequency data:
Frequent: between 1 and 10 out of 100 patients.
Uncommon: between 1 and 10 out of 1,000 patients
Rare: between 1 and 10 out of 10,000 patients
Very rare: in less than 1 out of 10,000 patients
Not known: cannot be estimated from available data
Infections
Frequent: Infections caused by resistant bacteria or fungi, such as oral and vaginal infections caused by Candida.
Blood and lymphatic system disorders
Uncommon: Low red blood cell count, low white blood cell count, low levels of certain white blood cells (neutrophils), decrease or increase in certain blood cells necessary for blood coagulation, increase in certain white blood cells (eosinophils), decrease in blood coagulation.
Very rare: Increase in blood coagulation, significant decrease in certain white blood cells (agranulocytosis).
Decrease in the number of red and white blood cells and platelets (pancytopenia)
Endocrine disorders
Very rare: Syndrome associated with alterations in water elimination and low sodium levels (SIADH).
Allergic reactions
Uncommon: Allergic reactions.
Rare: Severe, sudden, and generalized allergic reaction, including very rarely life-threatening shock (e.g., difficulty breathing, decreased blood pressure, rapid pulse), swelling (including possible swelling of the airways that can be life-threatening).
Abnormal laboratory test results
Uncommon: Increase in blood lipids (fats)
Rare: Increase in blood glucose, increase in blood uric acid.
Very rare: Loss of consciousness due to a severe decrease in blood sugar levels (hypoglycemic coma)
Psychiatric disorders
Uncommon: Anxiety, restlessness/agitation
Rare: Emotional instability, depression (in very rare cases leading to self-harm, such as suicidal thoughts or attempts), hallucinations.
Very rare: Depersonalization disorder (feeling of not being oneself), dementia (possibly leading to self-harm, such as suicidal thoughts or attempts).
Nervous system
Frequent: Headache, dizziness.
Uncommon: Tingling sensation (pins and needles) and/or numbness, alteration of taste (in very rare cases, loss of taste), confusion and disorientation, sleep disorders (predominantly insomnia), tremors, sensation of vertigo (feeling of spinning and falling), somnolence.
Rare: Disorders of skin sensation, alterations of smell (including loss of smell), abnormal dreams, concentration disorders, speech alteration, total or partial loss of memory, balance and coordination disorders (due to dizziness).
Very rare: Increased skin sensitivity.
Eyes
Uncommon: Vision disorders, including double and blurred vision.
Very rare: Transient loss of vision.
Ears
Rare: Ringing/noise in the ears, hearing impairment including deafness (usually reversible).
Cardiac system(see section 2 "What you need to know before taking Moxifloxacino Kern Pharma)
Frequent: Change in heart rhythm (ECG), in patients with low potassium levels in the blood.
Uncommon: Change in heart rhythm (ECG), palpitations, irregular and rapid heart rate, severe heart rhythm disorders, angina pectoris.
Rare: Abnormally rapid heart rate, fainting.
Very rare: Heart rhythm disorders, irregular heart rate that can be life-threatening, cardiac arrest.
Vascular system
Uncommon: Dilation of blood vessels.
Rare: Hypertension, hypotension.
Respiratory system
Uncommon: Difficulty breathing, including asthmatic conditions.
Gastrointestinal system
Frequent: Nausea, vomiting, abdominal and stomach pain, diarrhea.
Uncommon: Decreased appetite and food intake, flatulence and constipation, gastric discomfort (indigestion/acid reflux), stomach inflammation (gastritis), increase in a certain digestive enzyme in the blood (amylase).
Rare: Difficulty swallowing, mouth inflammation, severe diarrhea with blood and/or mucus (antibiotic-associated colitis, including pseudomembranous colitis) that, in very rare circumstances, can lead to life-threatening complications.
Liver
Frequent: Increase in certain liver enzymes in the blood (transaminases).
Uncommon: Alteration of liver function (including increase in a liver enzyme in the blood, LDH), increase in bilirubin in the blood, increase in a liver enzyme in the blood (gamma-glutamyltransferase and/or alkaline phosphatase).
Rare: Jaundice (yellowing of the whites of the eyes or skin), liver inflammation.
Very rare: Fulminant liver inflammation with life-threatening liver failure (including fatal cases).
Skin
The most serious side effectsobserved during treatment with moxifloxacino are listed below:
Uncommon: Itching, rash, urticaria, dry skin, skin rashes.
Very rare: Inflammation of blood vessels (signs can be red spots on the skin, usually on the legs or effects such as joint pain).
Severe skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These can appear on the trunk as reddish spots in a target shape or circular patches, often with blisters in the center, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes, and can be preceded by fever and flu-like symptoms (with possible life-threatening consequences).
Not known: Increased skin sensitivity to sunlight or UV radiation (see also section 2. Warnings and precautions).
Clearly defined erythematous patches with/without blisters that appear in the hours following the administration of moxifloxacino and disappear with residual post-inflammatory hyperpigmentation; they usually reappear in the same place on the skin or mucous membrane with subsequent exposure to moxifloxacino.
Musculoskeletal system
Uncommon: Joint and muscle pain.
Rare: Tendon pain and inflammation (tendinitis), muscle cramps, muscle spasms, muscle weakness.
Very rare: Tendon rupture, joint inflammation, muscle stiffness, worsening of myasthenia gravis symptoms.
Not known: Muscle weakness, sensitivity, or pain, particularly if you also feel unwell, have a fever, or your urine is dark. These symptoms can be caused by abnormal muscle breakdown that can be life-threatening and cause kidney problems (a condition called rhabdomyolysis).
Kidneys
Uncommon: Dehydration.
Rare: Kidney disorders (including increased laboratory test results for the kidneys, such as urea and creatinine), kidney failure.
General disorders
Uncommon: Malaise (mainly weakness or fatigue), back, limb, pelvis, and thorax pain, sweating.
Rare: Swelling (of hands, feet, ankles, lips, mouth, and throat).
Very rare cases of long-lasting (even months or years) or permanent adverse reactions, such as tendon inflammation, tendon rupture, joint pain, limb pain, difficulty walking, abnormal sensations (such as pins and needles, tingling, burning, numbness, or pain), fatigue, decreased memory and concentration, effects on mental health (including sleep disorders, anxiety, panic attacks, depression, and suicidal ideation), as well as decreased hearing, vision, taste, and smell, have been associated with the administration of quinolone and fluoroquinolone antibiotics, in some cases regardless of the presence of pre-existing risk factors.
Additionally, very rare cases of the following side effects, described after treatment with other quinolone antibiotics and which may also occur during treatment with moxifloxacino, have been reported: increased sodium and calcium levels in the blood, reduced count of a certain type of red blood cell (hemolytic anemia), problems associated with the nervous system, such as pain, burning, tingling, numbness, and/or weakness in the limbs.
There have been reports of increased size and weakening or tearing of the aortic wall (aneurysms and dissections), which could lead to rupture and be fatal, and heart valve disorders in patients who have received fluoroquinolones. See also section 2.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System for human use: http://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging after "EXP". The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and unused medications at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Moxifloxacino Kern Pharma
Appearance and packaging of the product
Rosa-colored, oblong, and biconvex film-coated tablets.
Each normal package contains aluminum/aluminum blisters of 5 or 7 film-coated tablets.
Each clinical package contains aluminum/aluminum blisters of 100 film-coated tablets.
Marketing authorization holder
Kern Pharma, S.L.
Venus, 72 - Pol. Ind. Colón II
08228 Terrassa - Barcelona
Spain
Manufacturer
Pharmathen International S.A.
Industrial Park Sapes,
Rodopi Prefecture, Block N 5, 69300 Rodopi
Greece
or
Pharmaten S.A.
Dervenakion, 6 Pallini, 15351 Attiki
Greece
Date of the last revision of this leaflet:May 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of MOXIFLOXACIN KERN PHARMA 400 mg FILM-COATED TABLETS in November, 2025 is around 13.58 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for MOXIFLOXACIN KERN PHARMA 400 mg FILM-COATED TABLETS – subject to medical assessment and local rules.